Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 3/20 | 0.32 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.32 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552057 | 0.84 | MAPT (0.42) | HCRTR2HCRTR1IRAK4GRM5MAPT | |
| SCHEMBL20594858 | 0.81 | IRAK4 (0.51) | HCRTR2HCRTR1HRH3CRBNIRAK4 | |
| SCHEMBL2547518 | 0.78 | HRH3 (0.47) | HCRTR2HCRTR1HRH3CRBNKMT2A | |
| SCHEMBL2550688 | 0.77 | CRBN (0.50) | HCRTR2HCRTR1HRH3CRBNMAOA | |
| SCHEMBL28003510 | 0.72 | HRH3 (0.42) | HCRTR2HCRTR1HRH3CRBNMAOA | |
| SCHEMBL15357058 | 0.71 | HRH3 (0.50) | HCRTR2HCRTR1HRH3CRBNMAOA | |
| SCHEMBL28003538 | 0.71 | HRH3 (0.41) | HCRTR2HCRTR1HRH3CRBNIRAK4 | |
| SCHEMBL20031574 | 0.69 | HRH3 (0.55) | HCRTR2HCRTR1HRH3CRBNMAOA | |
| SCHEMBL13638866 | 0.69 | HRH3 (0.41) | HCRTR2HCRTR1HRH3CRBNMAOA | |
| SCHEMBL2554680 | 0.69 | HRH3 (0.58) | HCRTR2HCRTR1HRH3CRBNMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200125564-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2020-04-23 | — | — | US | disclosed |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2020-01-28 | — | — | US | disclosed |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-09-04 | — | — | US | disclosed |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2018-07-12 | — | — | US | disclosed |
| US-9926325-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-03-27 | — | — | US | disclosed |
| EP-3176171-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2552920-B1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20150315199-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2015-11-05 | — | — | US | disclosed |
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8871761-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | EUROSCREEN S.A. (BE) | 2014-10-28 | — | — | US | disclosed |
| EP-2552920-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | Euroscreen S.A. (BE) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| WO-2011121137-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | HCRTR2 348/4885HCRTR1 474/4885HRH3 75/4885 |
| US-10065960-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | HCRTR2 466/4885HCRTR1 562/4885HRH3 58/4885 |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | HCRTR2 348/4885HCRTR1 474/4885HRH3 75/4885 |
| US-20150315199-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | HCRTR2 348/4885HCRTR1 474/4885HRH3 75/4885 |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | HCRTR2 348/4885HCRTR1 474/4885HRH3 75/4885 |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | HCRTR2 466/4885HCRTR1 562/4885HRH3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.